The results demonstrated that HER2-positive breast cancer patients were more likely to achieve ypN0 status after NAT when achieving breast pCR, presenting with histologic grade III tumors, exhibiting HER2 IHC 3+ expression, lacking lymphovascular invasion, demonstrating clinical N1 stage, and showing prominent and hypervascular tumor CDFI signal pre-NAT (Table 5). The gene discussed is ERBB2; the disease is breast cancer.